Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Glassock

Nephrology Laguna Niguel, CA Medical Doctor

NPI 1649548579 CMS profile 256073

8 Bethany, Laguna Niguel, CA 92677

Open in the dashboard

General payments

$137,957

172 records reported · program years 2019–2025

Research payments

$34,151

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Glassock of Laguna Niguel, CA is reported in the CMS Open Payments database as having received $137,957 across 172 general payments and $34,151 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31,786 49
2025 Research $21,685 1
2024 General $35,716 46
2024 Research $7,228 1
2023 General $9,334 14
2022 General $16,942 17
2021 General $20,115 16
2020 General $16,122 15
2020 Research $2,013 1
2019 General $7,943 15
2019 Research $3,225 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Glassock
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Richard Glassock were reported at $31,786. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Richard Glassock Nephrology median Middle half National median
2019 $7,943 $236 $90–$588 $163
2020 $16,122 $135 $46–$364 $114
2021 $20,115 $202 $67–$551 $132
2022 $16,942 $242 $77–$695 $149
2023 $9,334 $254 $84–$766 $160
2024 $35,716 $300 $99–$852 $164
2025 $31,786 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. BioCryst Pharmaceuticals, Inc. $30,863 17 payments
  2. Novartis Pharmaceuticals Corporation $28,942 50 payments
  3. Alexion Pharmaceuticals, Inc. $16,062 16 payments
  4. Otsuka Pharmaceutical Development & Commercialization, Inc. $13,993 5 payments
  5. Otsuka America Pharmaceutical, Inc. $9,316 3 payments
  6. Retrophin, Inc. $8,728 18 payments
  7. F. Hoffmann-La Roche AG $6,588 4 payments
  8. Omeros Corporation $5,901 6 payments
  9. Mallinckrodt Enterprises LLC $4,918 6 payments
  10. Horizon Therapeutics plc $3,323 7 payments
  11. Other $9,323 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $120,619 56 payments
  2. Food and Beverage $8,697 97 payments
  3. Travel and Lodging $7,127 17 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,500 1 payment
  5. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. Fabhalta $9,332 14 payments
  2. Narsoplimab $5,850 5 payments
  3. ACTHAR $4,918 6 payments
  4. GAZYVA $2,323 4 payments
  5. KRYSTEXXA $2,123 4 payments
  6. ENTRESTO $526 6 payments
  7. LUPKYNIS $294 4 payments
  8. Ozempic $273 3 payments
  9. Kerendia $251 3 payments
  10. PRALUENT $225 2 payments
  11. Other $1,692 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $28,913 2 payments
  2. E.R. Squibb & Sons, L.L.C. $4,113 2 payments
  3. Omeros Corporation $1,125 2 payments

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record